$ALLR
Allarity Therapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000121390023066893 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.480M $3.051M
YoY Change 59.18% 4.24%
% of Gross Profit
Research & Development $1.948M $1.105M
YoY Change -35.15% -21.18%
% of Gross Profit
Depreciation & Amortization $10.00K $9.000K
YoY Change -9.09% -62.5%
% of Gross Profit
Operating Expenses $4.426M $4.156M
YoY Change -2.98% -4.0%
Operating Profit -$4.426M -$4.156M
YoY Change -2.98% -14.17%
Interest Expense $34.00K $142.0K
YoY Change -2.86% -70.17%
% of Operating Profit
Other Income/Expense, Net -$21.00K $1.776M
YoY Change -95.53% -322.0%
Pretax Income -$4.450M -$2.380M
YoY Change -11.57% -48.85%
Income Tax
% Of Pretax Income
Net Earnings -$4.447M -$2.380M
YoY Change -11.71% -48.89%
Net Earnings / Revenue
Basic Earnings Per Share -$2.24 -$26.28
Diluted Earnings Per Share -$2.03 -$26.28
COMMON SHARES
Basic Shares Outstanding 2.729M shares 19.14M shares
Diluted Shares Outstanding 2.475M shares 372.4K shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.400M $420.0K
YoY Change -64.52% -94.5%
Cash & Equivalents $1.399M $420.0K
Short-Term Investments
Other Short-Term Assets $1.029M $1.495M
YoY Change 465.38% 34.44%
Inventory
Prepaid Expenses $396.0K $220.0K
Receivables
Other Receivables
Total Short-Term Assets $4.387M $3.686M
YoY Change -27.62% -63.44%
LONG-TERM ASSETS
Property, Plant & Equipment $29.00K $26.00K
YoY Change 480.0% -44.68%
Goodwill
YoY Change
Intangibles $9.714M
YoY Change -24.17%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $9.488M $9.740M
YoY Change -21.41% -25.72%
TOTAL ASSETS
Total Short-Term Assets $4.387M $3.686M
Total Long-Term Assets $9.488M $9.740M
Total Assets $13.88M $13.43M
YoY Change -23.49% -42.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.347M $8.089M
YoY Change 34.84% 45.62%
Accrued Expenses $1.485M $1.921M
YoY Change -63.59% 58.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $350.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.74M $12.67M
YoY Change 21.53% 13.2%
LONG-TERM LIABILITIES
Long-Term Debt $1.170M $1.138M
YoY Change 10.69% 10.38%
Other Long-Term Liabilities $0.00 -$50.00
YoY Change
Total Long-Term Liabilities $1.170M $1.138M
YoY Change 10.69% 10.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.74M $12.67M
Total Long-Term Liabilities $1.170M $1.138M
Total Liabilities $17.25M $14.15M
YoY Change 17.93% 9.87%
SHAREHOLDERS EQUITY
Retained Earnings -$92.73M -$88.28M
YoY Change 16.33% 18.22%
Common Stock $0.00 $0.00
YoY Change -100.0% -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.379M -$723.0K
YoY Change
Total Liabilities & Shareholders Equity $13.88M $13.43M
YoY Change -23.49% -42.11%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$4.447M -$2.380M
YoY Change -11.71% -48.89%
Depreciation, Depletion And Amortization $10.00K $9.000K
YoY Change -9.09% -62.5%
Cash From Operating Activities -$5.370M -$2.496M
YoY Change 21.82% -36.15%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.450M 2.865M
YoY Change -223.97%
NET CHANGE
Cash From Operating Activities -5.370M -2.496M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 6.450M 2.865M
Net Change In Cash 1.080M 369.0K
YoY Change -124.5% -105.93%
FREE CASH FLOW
Cash From Operating Activities -$5.370M -$2.496M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41160
dei Entity Registrant Name
EntityRegistrantName
ALLARITY THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-2147982
dei Entity Address Address Line1
EntityAddressAddressLine1
24 School Street
dei Entity Address Address Line2
EntityAddressAddressLine2
2nd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02108
dei City Area Code
CityAreaCode
(401)
dei Local Phone Number
LocalPhoneNumber
426-4664
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
ALLR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2728823 shares
CY2023Q2 us-gaap Cash
Cash
420000 usd
CY2022Q4 us-gaap Cash
Cash
2029000 usd
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1495000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1559000 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
220000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
591000 usd
CY2023Q2 us-gaap Income Tax Receivable
IncomeTaxReceivable
1551000 usd
CY2022Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
789000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
3686000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
4968000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6000 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9714000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9549000 usd
CY2023Q2 us-gaap Assets
Assets
13426000 usd
CY2022Q4 us-gaap Assets
Assets
14544000 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
8089000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6251000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1921000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1904000 usd
CY2023Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
36000 usd
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
41000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8000 usd
CY2023Q2 allr Warrant Liability
WarrantLiability
1129000 usd
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1143000 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
374000 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
350000 usd
CY2022Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
2644000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12668000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11222000 usd
CY2023Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1138000 usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1083000 usd
CY2023Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
343000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
349000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
14149000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
12654000 usd
CY2022Q4 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
2003000 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 allr Preferred Stock Share Designated
PreferredStockShareDesignated
20000 shares
CY2022Q4 allr Preferred Stock Share Designated
PreferredStockShareDesignated
20000 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
6047 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
6047 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
13586 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
13586 shares
CY2023Q2 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
75000 usd
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
5637000 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
503600 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
503600 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
454225 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
454225 shares
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
82588000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
83158000 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-666000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-721000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-88282000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82550000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-723000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-113000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13426000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14544000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1105000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1696000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2532000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2985000 usd
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
14007000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3051000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3146000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5292000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6159000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
4156000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
4842000 usd
us-gaap Operating Expenses
OperatingExpenses
7824000 usd
us-gaap Operating Expenses
OperatingExpenses
23151000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4156000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4842000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7824000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-23151000 usd
allr Proceeds From Sales Of Ip
ProceedsFromSalesOfIP
-1780000 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
7000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
5000 usd
allr Partial Liquid Damage Interest Rate
PartialLiquidDamageInterestRate
0.18 pure
CY2023Q2 us-gaap Interest Expense
InterestExpense
142000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
33000 usd
us-gaap Interest Expense
InterestExpense
234000 usd
us-gaap Interest Expense
InterestExpense
72000 usd
CY2022Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
-34000 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
-70000 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-26000 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-269000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
69000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-538000 usd
CY2023Q2 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
1941000 usd
CY2022Q2 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
874000 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
2250000 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
13440000 usd
CY2022Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-800000 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-800000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1776000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-257000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2092000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13745000 usd
CY2023Q2 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-2380000 usd
CY2022Q2 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-5099000 usd
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-5732000 usd
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-9406000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1223000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2380000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5103000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5732000 usd
us-gaap Net Income Loss
NetIncomeLoss
-8183000 usd
CY2023Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
119000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
123000 usd
CY2023Q2 us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
7287000 usd
us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
7287000 usd
us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
1572000 usd
CY2022Q2 us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
1377000 usd
us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
1511000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9786000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6480000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13142000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11266000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-26.28
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-53.9
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-66.82
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-97.63
us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
34
us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
816345 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
372414 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
120223 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
196677 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115394 shares
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2380000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5103000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5732000 usd
us-gaap Net Income Loss
NetIncomeLoss
-8183000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
29000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
414000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-55000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
628000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2409000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5517000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5677000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8811000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18152000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
381000 usd
CY2022Q1 allr Deemed Dividend Percentage1
DeemedDividendPercentage1
0.08 pure
CY2022Q1 allr Deemed Dividend Of Preferred Stock
DeemedDividendOfPreferredStock
1572000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1065000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-214000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3080000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
14732000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
26000 usd
CY2022Q2 allr Floor Price Liability
FloorPriceLiability
-1377000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
161000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-59000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-414000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5103000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
7966000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-113000 usd
CY2023Q1 allr Deemed Dividend Of Preferred Stock
DeemedDividendOfPreferredStock
167000 usd
CY2023Q1 us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
565000 usd
CY2023Q1 allr Redemption Of Series A Preferred Stock Amount
RedemptionOfSeriesAPreferredStockAmount
2000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-121000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
84000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3352000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-3102000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
6815000 usd
CY2023Q2 allr Fair Value Of April Warrants Allocated To Liabilities Net Of Financing Costs
FairValueOfAprilWarrantsAllocatedToLiabilitiesNetOfFinancingCosts
-3772000 usd
CY2023Q2 us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
812000 usd
CY2023Q2 allr Deemed Dividends On Series A Preferred Stock
DeemedDividendsOnSeriesAPreferredStock
-119000 usd
CY2023Q2 allr Eliminations Of Series A Redemption Rights
EliminationsOfSeriesARedemptionRights
624000 usd
CY2023Q2 allr Issuance Of Series A Preferred Stock As Repayment Of Debt
IssuanceOfSeriesAPreferredStockAsRepaymentOfDebt
453000 usd
CY2023Q2 allr Redemption Of Series A Preferred Stock For Cancellation Of Debt
RedemptionOfSeriesAPreferredStockForCancellationOfDebt
-1652000 usd
CY2023Q2 allr Exchange Of Series C Preferred Stock For Series A Preferred Stock Amount
ExchangeOfSeriesCPreferredStockForSeriesAPreferredStockAmount
1447000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
180000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-29000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2380000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-723000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5732000 usd
us-gaap Net Income Loss
NetIncomeLoss
-8183000 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
1780000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
800000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
19000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
47000 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
14007000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
59000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1006000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
59000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-538000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-376000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
200000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
52000 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
-70000 usd
allr Fair Value Adjustment Of Derivative Liabilities
FairValueAdjustmentOfDerivativeLiabilities
-2250000 usd
allr Fair Value Adjustment Of Derivative Liabilities
FairValueAdjustmentOfDerivativeLiabilities
-13440000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1223000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
26000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-355000 usd
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
762000 usd
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
593000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-371000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
887000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1838000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5175000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
282000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5820000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-5000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-34000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-8000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-53000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5697000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9963000 usd
us-gaap Proceeds From Sale Of Investment Projects
ProceedsFromSaleOfInvestmentProjects
809000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
809000 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
1160000 usd
allr Redemption Of Series B Preferred Stock
RedemptionOfSeriesBPreferredStock
2000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1050000 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
6815000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3348000 usd
allr Redemption Of Series A Preferred Stock
RedemptionOfSeriesAPreferredStock
1652000 usd
allr Cash Paid In Connection With Conversion Of Series A Preferred Stock
CashPaidInConnectionWithConversionOfSeriesAPreferredStock
1511000 usd
allr Penalty On Series A Preferred Stock Liability
PenaltyOnSeriesAPreferredStockLiability
800000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4023000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2311000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1674000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11465000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-413000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2029000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19555000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
420000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7677000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
6000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
1000 usd
us-gaap Interest Paid Net
InterestPaidNet
79000 usd
us-gaap Interest Paid Net
InterestPaidNet
20000 usd
allr Gain On Sale Of Ip
GainOnSaleOfIP
971000 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
3334000 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
701000 usd
us-gaap Stock Issued1
StockIssued1
5199000 usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
453000 usd
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
3328000 usd
allr Deemed Dividend On Exchange Of Series C Preferred Stock For Series A Preferred Stock
DeemedDividendOnExchangeOfSeriesCPreferredStockForSeriesAPreferredStock
3752000 usd
allr Deemed Dividend On Redemption Of Series A Preferred Stock
DeemedDividendOnRedemptionOfSeriesAPreferredStock
207000 usd
allr Deemed Dividend On Series A Preferred Stock
DeemedDividendOnSeriesAPreferredStock
1572000 usd
allr Deemed Dividend On Series C Convertible Preferred Stock And Accretion Of Series C Preferred Sh
DeemedDividendOnSeriesCConvertiblePreferredStockAndAccretionOfSeriesCPreferredSh
123000 usd
allr Financial Term
FinancialTerm
P1Y
CY2023Q2 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
88300000 usd
CY2023Q2 us-gaap Decommissioning Fund Investments
DecommissioningFundInvestments
420000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(a) Use of Estimates and Assumptions</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting years. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the fair value of the Series A, Series B, and Series C Preferred Stock, warrants, convertible debt, convertible promissory note, and the accrual for research and development expenses, fair values of acquired intangible assets and impairment review of those assets, share based compensation expense, and income tax uncertainties and valuation allowances. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed considering reasonable changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known and if material, their effects are disclosed in the notes to the financial statements. Actual results could differ from those estimates or assumptions.</p>
CY2022 allr Intangible Assets Utilizing A Discounted
IntangibleAssetsUtilizingADiscounted
0.26 pure
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
3564000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><i>(c) Concentrations of credit risk and of significant suppliers</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash. The Company maintains its cash in financial institutions in amounts that could exceed government-insured limits. The Company does not believe it is subject to additional credit risks beyond those normally associated with commercial banking relationships. The Company has not experienced losses on its cash accounts and management believes, based upon the quality of the financial institutions, that the credit risk regarding these deposits is not significant. The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply its requirements for supplies and raw materials related to these programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><i> </i></p>
CY2023Q2 us-gaap Allowance For Loan And Lease Losses Foreign Currency Translation
AllowanceForLoanAndLeaseLossesForeignCurrencyTranslation
-29000 usd
CY2022Q2 us-gaap Allowance For Loan And Lease Losses Foreign Currency Translation
AllowanceForLoanAndLeaseLossesForeignCurrencyTranslation
-414000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
55000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
-628000 usd
CY2023Q2 us-gaap Inventory Real Estate Improvements
InventoryRealEstateImprovements
9714000 usd
CY2022Q2 us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
usd
CY2023Q2 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
378000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
387000 usd
CY2023Q2 us-gaap Deposit Assets
DepositAssets
57000 usd
CY2022Q4 us-gaap Deposit Assets
DepositAssets
51000 usd
CY2023Q2 allr Salary Deposit
SalaryDeposit
82000 usd
CY2022Q4 allr Salary Deposit
SalaryDeposit
85000 usd
CY2023Q2 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
52000 usd
CY2022Q4 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
82000 usd
CY2023Q2 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
718000 usd
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
81000 usd
allr Deferred Directors Officers Insurance Expense
DeferredDirectorsOfficersInsuranceExpense
586000 usd
CY2022 allr Deferred Directors Officers Insurance Expense
DeferredDirectorsOfficersInsuranceExpense
1260000 usd
allr Net Other Current Asset
NetOtherCurrentAsset
1495000 usd
CY2022 allr Net Other Current Asset
NetOtherCurrentAsset
1559000 usd
allr Intangible Assets Utilizing A Discounted
IntangibleAssetsUtilizingADiscounted
0.26 pure
CY2022Q2 us-gaap Percentage Of Weighted Average Cost Inventory
PercentageOfWeightedAverageCostInventory
0.16 pure
us-gaap Impairment Charge On Reclassified Assets
ImpairmentChargeOnReclassifiedAssets
14007000 usd
CY2022Q4 us-gaap Inventory Real Estate Improvements
InventoryRealEstateImprovements
9549000 usd
CY2023Q2 allr Development Cost Liability
DevelopmentCostLiability
1256000 usd
CY2022Q4 allr Development Cost Liability
DevelopmentCostLiability
964000 usd
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
300000 usd
CY2023Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
177000 usd
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
221000 usd
CY2023Q2 allr Accrued Board Member Fees
AccruedBoardMemberFees
43000 usd
CY2022Q4 allr Accrued Board Member Fees
AccruedBoardMemberFees
91000 usd
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
100000 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
239000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
45000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
389000 usd
CY2023Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
1921000 usd
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
1904000 usd
CY2022Q2 us-gaap Investment Owned Balance Principal Amount
InvestmentOwnedBalancePrincipalAmount
1000000 usd
CY2023Q2 allr Interest Payable Percentage
InterestPayablePercentage
0.05 pure
allr Equity Securities Rate
EquitySecuritiesRate
0.03 pure
us-gaap Interest And Debt Expense
InterestAndDebtExpense
55000 usd
us-gaap Interest And Debt Expense
InterestAndDebtExpense
52000 usd
CY2023Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1000000 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1000000 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
162000 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
215000 usd
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
25000 usd
CY2022 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
53000 usd
CY2023Q2 us-gaap Convertible Debt
ConvertibleDebt
863000 usd
CY2022Q4 us-gaap Convertible Debt
ConvertibleDebt
838000 usd
us-gaap Interest Expense Other
InterestExpenseOther
245000 usd
CY2022 us-gaap Interest Expense Other
InterestExpenseOther
194000 usd
us-gaap Accretion Expense
AccretionExpense
30000 usd
CY2022 us-gaap Accretion Expense
AccretionExpense
51000 usd
CY2023Q2 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
1138000 usd
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
1083000 usd
CY2022Q4 allr Principal Amount
PrincipalAmount
1667000 usd
CY2022Q4 us-gaap Payments For Rent
PaymentsForRent
1667000 usd
CY2022Q4 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
350000 usd
CY2022Q4 us-gaap Investment Sold Not Yet Purchased Balance Principal Amount
InvestmentSoldNotYetPurchasedBalancePrincipalAmount
650000 usd
us-gaap Sale Leaseback Transaction Gross Proceeds Financing Activities
SaleLeasebackTransactionGrossProceedsFinancingActivities
5000000 usd
us-gaap Debt Instrument Redemption Price Percentage Of Principal Amount Redeemed
DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
0.35 pure
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
34000 usd
CY2023Q2 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
43000 usd
CY2023Q2 allr Contractual Interest
ContractualInterest
33000 usd
CY2023Q2 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
10000 usd
CY2023Q2 us-gaap Loan Processing Fee
LoanProcessingFee
350000 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
71734 shares
CY2023Q2 us-gaap Payments For Fees
PaymentsForFees
3348000 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2667000 usd
CY2022 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2667000 usd
us-gaap Proceeds From Short Term Debt Maturing In Three Months Or Less
ProceedsFromShortTermDebtMaturingInThreeMonthsOrLess
32000 usd
CY2022 us-gaap Proceeds From Short Term Debt Maturing In Three Months Or Less
ProceedsFromShortTermDebtMaturingInThreeMonthsOrLess
35000 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
9000 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
2000 usd
CY2023Q2 us-gaap Time Deposits At Carrying Value
TimeDepositsAtCarryingValue
2644000 usd
CY2022Q4 us-gaap Time Deposits At Carrying Value
TimeDepositsAtCarryingValue
2634000 usd
us-gaap Temporary Equity Accretion Of Interest
TemporaryEquityAccretionOfInterest
10000 usd
CY2023Q2 us-gaap Income Tax Examination Interest Accrued
IncomeTaxExaminationInterestAccrued
33000 usd
CY2022Q4 us-gaap Income Tax Examination Interest Accrued
IncomeTaxExaminationInterestAccrued
10000 usd
us-gaap Change In Unrealized Gain Loss On Hedged Item In Fair Value Hedge1
ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
2687000 usd
CY2022 us-gaap Change In Unrealized Gain Loss On Hedged Item In Fair Value Hedge1
ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
2644000 usd
us-gaap Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less
ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
-2687000 usd
CY2023Q2 us-gaap Notes Payable
NotesPayable
350000 usd
CY2023Q2 allr Convertible Promissory Note Net Ending Balance
ConvertiblePromissoryNoteNetEndingBalance
350000 usd
CY2022Q4 allr Convertible Promissory Note Net Ending Balance
ConvertiblePromissoryNoteNetEndingBalance
2644000 usd
CY2022Q4 us-gaap Variable Interest Entity Ownership Percentage
VariableInterestEntityOwnershipPercentage
0.0999 pure
CY2022Q4 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
9.906
CY2023Q2 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
30
CY2023Q2 allr Stated Value Share
StatedValueShare
1080000 usd
CY2023Q2 allr Description Of Exchange Agreement
DescriptionOfExchangeAgreement
(i) amend the Certificate of Designations for the Series A Convertible Preferred Stock (the “Amended COD”), which among other things, eliminates the Series A Preferred Stock redemption right and dividend (except for certain exceptions as specified in the Amended COD), and provides for the conversion of Series A Preferred Stock into Common Stock at a conversion price of $0.75 which is equal to the price for a share of Common Stock sold in the April Offering, (ii) exchange 50,000 shares of Series C Preferred Stock (the “Series C Shares”) beneficially owned by 3i for 5,577 shares of Series A Preferred Stock (the “Exchange Shares”), (iii) exchange a warrant to purchase common stock issued on December 20, 2021 to 3i (the “Original Warrant”) for a new warrant (the “Exchange Warrant”), which reflects an exercise price of $30.00 (the “New Exercise Price”) and represents a right to acquire 315,085 shares of Common Stock (the “New Warrant Shares”).
us-gaap Dividend Income Operating Paid In Cash
DividendIncomeOperatingPaidInCash
1652000 usd
allr Accrued Percentage
AccruedPercentage
0.18 pure
CY2023Q2 us-gaap Financing Receivable Excluding Accrued Interest Nonaccrual Percent Past Due
FinancingReceivableExcludingAccruedInterestNonaccrualPercentPastDue
0.18 pure
CY2023Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
1.25 pure
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
0.02 pure
CY2022Q2 allr Securities Purchase Agreement Percentage
SecuritiesPurchaseAgreementPercentage
0.02 pure
CY2022Q2 us-gaap Financing Receivable Excluding Accrued Interest Nonaccrual Percent Past Due
FinancingReceivableExcludingAccruedInterestNonaccrualPercentPastDue
0.02 pure
CY2022Q2 allr Accrue Payments Percent
AccruePaymentsPercent
0.02 pure
CY2023Q2 us-gaap Derivative Net Liability Position Aggregate Fair Value
DerivativeNetLiabilityPositionAggregateFairValue
539000 usd
CY2022Q2 us-gaap Derivative Net Liability Position Aggregate Fair Value
DerivativeNetLiabilityPositionAggregateFairValue
539000 usd
CY2023Q2 allr Warrant Exchange Shares
WarrantExchangeShares
315085 shares
CY2023Q2 allr Exercisable Per Shares
ExercisablePerShares
30
allr Fair Value Percentage
FairValuePercentage
0.10 pure
CY2023Q2 us-gaap Liabilities Average Amount Outstanding
LiabilitiesAverageAmountOutstanding
3952000 usd
CY2023Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
624000 usd
CY2023Q2 us-gaap Investment Income Dividend
InvestmentIncomeDividend
3328000 usd
us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
3899000 usd
allr Converted Preferred Stock
ConvertedPreferredStock
613000 usd
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
1511000 usd
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
1511000 usd
CY2022Q1 allr Stock Trading
StockTrading
2500000 usd
CY2022Q1 allr Percentage Of Deemed Dividend
PercentageOfDeemedDividend
0.08 pure
CY2022Q1 allr Converted Preferred Stock
ConvertedPreferredStock
1572000 usd
CY2022Q1 allr Registration Delay Payment
RegistrationDelayPayment
800000 usd
CY2023Q1 allr Sale Of Purchase Shares
SaleOfPurchaseShares
50000 shares
CY2023Q1 us-gaap Payments For Proceeds From Previous Acquisition
PaymentsForProceedsFromPreviousAcquisition
1200000 usd
CY2023Q1 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
50000 shares
allr Expiration Of The Allowable Price Percentage
ExpirationOfTheAllowablePricePercentage
0.02 pure
us-gaap Debt Instrument Redemption Description
DebtInstrumentRedemptionDescription
The Company has evaluated the terms of the Series C Preferred Stock as required pursuant to ASC 570, 480, 815 and ASU 2020-06, and concluded the Series C Preferred Stock will be recorded at fair value of $1,200, net of share issuance costs of $40, and accreted dividends at 5% to redemption value of $1,446 on April 21, 2023, using the effective interest method.
CY2023Q2 allr Fair Value Amount
FairValueAmount
5200000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1240000 usd
us-gaap Investment Income Dividend
InvestmentIncomeDividend
3959000 usd
us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
1200000 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
40000 usd
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.05 pure
us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
286000 usd
CY2023Q2 allr Series C Preferred Stock Total
SeriesCPreferredStockTotal
1446 shares
allr Exchange Of Series C Preferred Stock For Series A Preferred Stock
ExchangeOfSeriesCPreferredStockForSeriesAPreferredStock
1446000 usd
CY2023Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1143000 usd
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
374000 usd
allr Common Stock Description
CommonStockDescription
a result of the filing of the Certificate of Amendment, the Company is authorized to issue 750,500,000 shares, consisting of (i) 750,000,000 shares of common stock, par value $0.0001 per share, and (ii) 500,000 shares of preferred stock, par value of $0.0001 per share.
CY2023Q2 us-gaap Common Stock Other Shares Outstanding
CommonStockOtherSharesOutstanding
503566 shares
CY2023Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.0001
CY2023Q2 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
223857 shares
CY2023Q2 us-gaap Shares Issued
SharesIssued
71734 shares
CY2023Q2 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
71734 shares
CY2023Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
30
CY2023Q2 allr Pre Fund Warrants
PreFundWarrants
178267 shares
CY2023Q2 allr Aggregate Gross Proceeds
AggregateGrossProceeds
7500000 usd
allr Warrants Fair Value
WarrantsFairValue
4148000 usd
us-gaap Cost Of Revenue
CostOfRevenue
679000 usd
us-gaap Financing Interest Expense
FinancingInterestExpense
376000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
34
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
34
CY2023Q2 us-gaap Share Price
SharePrice
6.6
CY2023Q2 us-gaap Share Price
SharePrice
20.4
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.042 pure
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.037 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y9M21D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.26 pure
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.26 pure
CY2022Q2 allr Conversion Of Stock Shares Issued
ConversionOfStockSharesIssued
441005 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
190000 usd
CY2022Q2 us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
-1187000 usd
CY2023Q2 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
3899 shares
us-gaap Gross Profit
GrossProfit
-806000 usd
CY2022Q2 us-gaap Common Stocks Including Additional Paid In Capital Net Of Discount
CommonStocksIncludingAdditionalPaidInCapitalNetOfDiscount
1511000 usd
CY2022Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
2782 shares
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
180000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
59000 usd
CY2023Q2 us-gaap Prepaid Expense Other Noncurrent
PrepaidExpenseOtherNoncurrent
59000 usd
CY2023Q2 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
121000 usd
CY2022Q2 us-gaap Other General Expense
OtherGeneralExpense
20000 usd
CY2022Q2 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
39000 usd
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
59000 usd
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
1006000 usd
us-gaap Other General Expense
OtherGeneralExpense
20000 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
39000 usd
us-gaap Other General Expense
OtherGeneralExpense
664000 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
342000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
483 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9174
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P4Y1M20D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
71 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
13702
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
412 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7634
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y8M4D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
292 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8242
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y8M23D
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2023Q2 us-gaap Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
565497 shares
us-gaap Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
565497 shares
CY2022Q2 us-gaap Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
2032465 shares
us-gaap Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
2032465 shares
CY2023Q2 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
816345 shares
CY2022Q2 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
9276923 shares
us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
9276923 shares
CY2023Q2 allr Total Diluted Loss Per Share
TotalDilutedLossPerShare
1381842 shares
allr Total Diluted Loss Per Share
TotalDilutedLossPerShare
1381842 shares
CY2022Q2 allr Total Diluted Loss Per Share
TotalDilutedLossPerShare
11309388 shares
allr Total Diluted Loss Per Share
TotalDilutedLossPerShare
11309388 shares
CY2023Q2 allr Warrant Liability
WarrantLiability
1129000 usd
CY2023Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
1143000 usd
CY2023Q2 us-gaap Credit Risk Derivative Liabilities At Fair Value
CreditRiskDerivativeLiabilitiesAtFairValue
-2272000 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
374000 usd
CY2022Q4 us-gaap Credit Risk Derivative Liabilities At Fair Value
CreditRiskDerivativeLiabilitiesAtFairValue
-374000 usd
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
14007000 usd
us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
1223000 usd
CY2022Q1 allr Milestone Payment
MilestonePayment
500000 usd
CY2022Q1 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
5000000 usd
CY2022Q3 allr Outstanding Amount
OutstandingAmount
1000000 usd
us-gaap Federal Home Loan Bank Advances Activity For Year Average Balance Of Agreements Outstanding
FederalHomeLoanBankAdvancesActivityForYearAverageBalanceOfAgreementsOutstanding
3900000 usd
allr Obligated To Pay
ObligatedToPay
26500000 usd
CY2023Q2 us-gaap Contract With Customer Asset Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
1500000 usd
CY2023Q2 allr Novartis
Novartis
100 usd
CY2023Q3 allr Novartis
Novartis
300 usd
allr Minimum Patient Enrollment Description
MinimumPatientEnrollmentDescription
The Company agreed to pay Eisai in periodic payments as follows: (i) one hundred thousand dollars ($100) which has been paid; (ii) fifty thousand dollars ($50) within ten (10) days of execution of the fourth amendment which has been paid; (iii) one hundred thousand dollars ($100) upon completion of a capital raise (paid on July 18, 2023); and (iv) eight hundred and fifty thousand dollars (
CY2021 us-gaap Development Costs
DevelopmentCosts
1264000 usd
allr Cancellation Liability
CancellationLiability
1309000 usd
allr Agreement Amount
AgreementAmount
338000 usd
CY2022Q3 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
971000 usd
CY2022Q2 us-gaap Accrued Participation Liabilities Due In Next Operating Cycle
AccruedParticipationLiabilitiesDueInNextOperatingCycle
338000 usd
CY2023Q2 us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
usd
allr Royalty Payments Description
RoyaltyPaymentsDescription
i.a one-time upfront payment of $250 and $100 for stenoparib and dovitinib respectively, within 5 business days after January 2, 2022 ($350 received as of January 11, 2022, and recorded in other income as proceeds on sale of IP); and   ii. two milestone payments of $1,000 each due and payable upon receipt of regulatory approval of a product in the United States, and of a product in Europe, respectively. Pursuant to the Oncoheroes Agreement Allarity is also entitled to tiered royalties on aggregate net product sales (“Sales”) of between 7% and 12% on net sales of products as follows: 7% on Sales less than $100 million; 10% on Sales of greater than $100 million and less than $200 million; and 12% on Sales greater than $200 million.
us-gaap Payments For Purchase Of Other Assets1
PaymentsForPurchaseOfOtherAssets1
1000000 usd
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
459000 usd
us-gaap Stockholders Equity Other
StockholdersEquityOther
10000000 usd
us-gaap Stockholders Equity Other
StockholdersEquityOther
8000000 usd
CY2023Q2 us-gaap Price Risk Derivative Assets At Fair Value
PriceRiskDerivativeAssetsAtFairValue
1000 usd
CY2023Q3 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
1
CY2023Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
1000000000 usd
CY2023Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
4.5
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.5
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
usd
CY2022Q4 allr Warrant Liability
WarrantLiability
usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
usd
CY2023Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
usd
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
usd
allr Proceeds From Sales Of Ip
ProceedsFromSalesOfIP
usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
usd
CY2023Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
usd
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-26.28
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-53.90
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-66.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-97.63
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115394 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
120223 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
196677 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
372414 shares
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
usd
us-gaap Proceeds From Sale Of Investment Projects
ProceedsFromSaleOfInvestmentProjects
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
usd
allr Redemption Of Series B Preferred Stock
RedemptionOfSeriesBPreferredStock
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
usd
allr Redemption Of Series A Preferred Stock
RedemptionOfSeriesAPreferredStock
usd
allr Cash Paid In Connection With Conversion Of Series A Preferred Stock
CashPaidInConnectionWithConversionOfSeriesAPreferredStock
usd
allr Penalty On Series A Preferred Stock Liability
PenaltyOnSeriesAPreferredStockLiability
usd
allr Gain On Sale Of Ip
GainOnSaleOfIP
usd
us-gaap Stock Issued1
StockIssued1
usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
usd
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
usd
allr Deemed Dividend On Exchange Of Series C Preferred Stock For Series A Preferred Stock
DeemedDividendOnExchangeOfSeriesCPreferredStockForSeriesAPreferredStock
usd
allr Deemed Dividend On Redemption Of Series A Preferred Stock
DeemedDividendOnRedemptionOfSeriesAPreferredStock
usd
allr Deemed Dividend On Series A Preferred Stock
DeemedDividendOnSeriesAPreferredStock
usd
allr Deemed Dividend On Series C Convertible Preferred Stock And Accretion Of Series C Preferred Sh
DeemedDividendOnSeriesCConvertiblePreferredStockAndAccretionOfSeriesCPreferredSh
usd
CY2022Q4 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
usd
CY2023Q2 us-gaap Deferred Costs Current
DeferredCostsCurrent
usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
usd
CY2022 us-gaap Temporary Equity Accretion Of Interest
TemporaryEquityAccretionOfInterest
usd
CY2022 us-gaap Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less
ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
usd
allr Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Weighted Average Lifein Years Cancelled Or Expired
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeWeightedAverageLifeinYearsCancelledOrExpired
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001860657

Files In Submission

Name View Source Status
0001213900-23-066893-index-headers.html Edgar Link pending
0001213900-23-066893-index.html Edgar Link pending
0001213900-23-066893.txt Edgar Link pending
0001213900-23-066893-xbrl.zip Edgar Link pending
allr-20230630.xsd Edgar Link pending
f10q0623ex10-1_allarityther.htm Edgar Link pending
f10q0623ex31-1_allarityther.htm Edgar Link pending
f10q0623ex31-2_allarityther.htm Edgar Link pending
f10q0623ex32-1_allarityther.htm Edgar Link pending
f10q0623ex32-2_allarityther.htm Edgar Link pending
f10q0623_allarityther.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
allr-20230630_cal.xml Edgar Link unprocessable
allr-20230630_pre.xml Edgar Link unprocessable
allr-20230630_lab.xml Edgar Link unprocessable
allr-20230630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
f10q0623_allarityther_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending